- Home
- CNTY vs QNCX Comparison
CNTY vs QNCX Comparison
Compare CNTY & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | QNCX |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 32.3M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNTY | QNCX |
|---|---|---|
| Price | $0.83 | $31.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.83 | ★ $75.43 |
| AVG Volume (30 Days) | ★ 77.1K | 24.0K |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $3.19 | N/A |
| Revenue Next Year | $0.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $0.78 | $0.11 |
| 52 Week High | $2.38 | $45.50 |
Technical Indicators
Market Signals| Indicator | CNTY | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 18.08 | 55.64 |
| Support Level | N/A | $29.95 |
| Resistance Level | $1.33 | $34.08 |
| Average True Range (ATR) | 0.07 | 2.70 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 16.06 | 44.41 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.